Sleep drug could rewire brain to fight nicotine addiction
NCT ID NCT05630781
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 12 times
Summary
This study tests whether suvorexant, a drug approved for insomnia, can reduce cravings and brain responses linked to smoking in daily smokers. Researchers will also study how it affects thinking and reward processing in non-smokers. The goal is to understand if blocking a brain chemical called orexin can help prevent relapse in nicotine addiction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NICOTINE DEPENDENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
National Institute on Drug Abuse
RECRUITINGBaltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Nicotine-Free cigarette break the habit?
- Can sleep patterns explain racial gaps in smoking cravings?
- Quit smoking from your couch: teleconsultation put to the test
- Do newer IQOS devices change how people puff? study investigates
- Could a sleep medication curb nicotine cravings?
- E-Cigarettes may dull the Brain's response to smoking triggers